Vir

Vir Biotechnology, based in San Francisco, CA, specializes in leveraging the immune system to address critical unmet medical needs in infectious diseases and cancer. The company’s innovative technologies include a next-generation antibody platform and the PRO-XTEN protease-releasable masking technology, focusing on building transformative medicines for conditions such as chronic hepatitis delta, COVID-19, and Ebola.

With a highly experienced leadership team and a commitment to rapid clinical advancement, Vir Biotechnology aims to deliver impactful treatments to patients worldwide. The organization prioritizes collaboration and ingenuity, striving to improve patient outcomes through its comprehensive research and therapeutic focus.

Generated from the website